ESC 2026: Tirzepatide 5mg sustains cardiometabolic benefit with weight maintenance
On 28 August, at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, a post-hoc analysis of the…
Cardiovascular
-
-
ESC 2026: Evidence supporting SGLT2 inhibitors and finerenone in heart failure grows
At the 2026 European Society of Cardiology (ESC) Scientific Sessions, hosted in Munich, Germany, researchers and care providers assembled to…
-
ESC 2026: Aficamten breaks new ground in nonobstructive HCM
This year at the European Society of Cardiology (ESC) Scientific Sessions, findings from the ACACIA-HCM trial explored the effect of…
-
ESC 2026: Evolocumab explores new frontiers in CV disease prevention
This year at the European Society of Cardiology (ESC) Scientific Sessions, new findings were presented from a pre-specified analysis of…
-
Updated UK guidance for finerenone introduces new treatment for HF patients
The National Institute for Health and Care Excellence (NICE) in the UK recently published new guidance on the usage of…
-
Bayer’s heart failure drug bound for NHS on NICE recommendation
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Bayer’s non-steroidal heart failure drug, Kerendia (finerenone), for…
-
ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, researchers presented a meta-analysis of randomized trials…
-
ACC 2026: Lorundrostat lowers BP but raises hyperkalemia risk
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, investigators from Brazil presented a systematic review…
-
JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions
Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets…
-
JPM26: Pfizer’s Metsera deal supercharges its obesity strategy
Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the…
